

19 February 2024

To: Recipients of CLSI MR15-Ed1

From: Jennifer K. Adams, MLS(ASCP), MSHA  
Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of a correction made to CLSI MR15, *Piperacillin-Tazobactam Breakpoints for Pseudomonas aeruginosa*, 1st ed. The correction is described below and shown as highlighted text in the table excerpt.

**Table 1. Historical CLSI Piperacillin-Tazobactam Breakpoints Against *Pseudomonas aeruginosa*:**

The 2012 minimal inhibitory concentration (MIC) for the resistant interpretive category is listed incorrectly as  $\geq 28/4$ . The interpretive category has been corrected to read  $\geq 128/4$ .

**Table 1. Historical CLSI Piperacillin-Tazobactam Breakpoints Against *Pseudomonas aeruginosa***

Year	Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm <sup>a</sup>			Interpretive Categories and MIC Breakpoints, $\mu\text{g}/\text{mL}$		
	S	I	R	S	I	R
1992	$\geq 18$	-	$\leq 17$	$\leq 64/4$	-	$\geq 128/4$
2012 <sup>b</sup>	$\geq 21$	15-20 <sup>^</sup>	$\leq 14$	$\leq 16/4$	32/4-64/4 <sup>^</sup>	$\geq 128/4$
2023	$\geq 22$	18-21 <sup>^</sup>	$\leq 17$	$\leq 16/4^c$	32/4	$\geq 64/4$

Abbreviations: I, intermediate; MIC, minimal inhibitory concentration; R, resistant; S, susceptible.

Symbol: ^ designates agents that have the potential to concentrate in urine.

<sup>a</sup> Disk content 100/10  $\mu\text{g}$ .

<sup>b</sup> Based on a piperacillin-tazobactam dosage regimen of  $\geq 3.375$  g given every 6 hours.

<sup>c</sup> Based on a piperacillin-tazobactam dosage regimen of 4.5 g every 6 hours as a 30-minute or 3-hour infusion.

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).